ORIG3N's Series B Round

ORIG3N raised a round of funding on June 27, 2017.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based …

Articles about ORIG3N's Series B Round: